Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Dundee Corp T.DC.A

Alternate Symbol(s):  DDEJF

Dundee Corporation is a Canada-based holding company. Through its operating segments, the Company is a mining- focused investor primarily engaged in acquiring mineral resource assets. Its segments include mining investments, mining services, and corporate and others. Its asset base includes investments in precious and base metals projects across four continents. Its subsidiaries include Dundee Sustainable Technologies Inc. (Dundee Technologies), Dundee Resources Limited, and Goodman & Company, Investment Counsel Inc. The Dundee Sustainable Technologies Inc., a 78%-owned subsidiary developing patented sustainable precious and base metals extraction processes. Through the development of its patented processes, the GlassLock Process and the CLEVR Process, Dundee Technologies extracts precious and base metals from ores and concentrates, while stabilizing contaminants such as arsenic.


TSX:DC.A - Post by User

Comment by jrj90620on Nov 30, 2022 4:09pm
184 Views
Post# 35140955

RE:RE:TauRx Press Release

RE:RE:TauRx Press ReleaseSupporting a path to regulatory submissions, the most recent data from LUCIDITY shows sustained improvement in cognition over 18 months over pre-treatment levels in those participants with MCI due to AD, building on previous data shared in October 2022. This treatment effect was seen only at the 16 mg/day dose of HMTM. Sustained cognitive improvement over baseline has not been seen with any other late-stage treatment for Alzheimer's currently being studied. Coupled with the strong safety profile, convenient oral administration, and lack of need for more than routine clinical monitoring, this positions HMTM as a game-changing prospect for the future treatment of this global unmet need.
<< Previous
Bullboard Posts
Next >>